



Carla Pasternak's

Dividend Opportunities

STREETAUTHORITY

[About Us](#)

[DividendOpportunities.com](#)

[Issue Archives](#)

[Premium Content](#)

[Research Reports](#)

[Subscribe](#)

Wednesday, April 29, 2009



[Printer-Friendly](#) | [PDF Version](#) | [Whitelist Us](#) | [Trouble viewing images?](#)

Long-Term Swine Flu Play With +157% Dividend Growth

-- By Amy Calistri

By the time it dominated the headlines, it was already too late to contain the outbreak of swine flu. Originating in Mexico, cases have already been confirmed in the U.S., Britain, Spain, Canada, Israel and New Zealand. South Korea, Australia, Sweden and Switzerland have suspected swine flu victims under surveillance, awaiting confirmation.

And since investors seize any opportunity -- even one that comes on the heels of a potential pandemic -- swine flu-related investments were already in play by Monday morning. But sometimes investors think short term. So while the obvious plays have had their day, investors still have chance to capitalize on swine flu's long-term benefits to this solid dividend paying company.

(Full Story Below)

Also in Today's Issue...

Capture 14% Yields and Total Returns up to +185.6%

On the last trading day of 2009, 94% of the picks in this high-yielding portfolio were up. Most of them have returned more than +10%, and several have returned +100% or more. But the best part is that these picks carry stable yields of up to 14.3%!

[Go here to see for yourself.](#)

Turn a \$200 investment into \$1 Million

There's a reason penny stocks have been Wall Street's favorite hidden investment for years now: they give the best shot at winning it big.

[Click Here to get in on these Hidden Investments!](#)

Long-Term Swine Flu Play With +157% Dividend Growth

Once a major story breaks, it doesn't take the market long to identify the immediate winners and losers. So I wasn't surprised to see companies effected by the news of the swine flu outbreak move double-digits within the first few minutes of trading on Monday morning. But I was a little surprised that some of the longer-term beneficiaries had largely been ignored.

The Losers

Anything to do with Mexican travel and tourism were logical losers. Grupo Aeroportuario del Pacifico (NYSE: PAC) operates 12 airports in Mexico's tourist-oriented Pacific region; its shares lost -15.1% on Monday. Cruise lines that feature Mexican destinations like Carnival (NYSE: CCL) and Royal Caribbean (NYSE: RCL) also saw their share prices fall.

One Stock a Month is All You'll Ever Need

For the entire 2009 calendar year 100% of Amy Calistri's *Stock of the Month* picks have been winners. ALL of her picks are up -- as much as +58.4% in just a few months. And her subscribers are making money hand over fist alongside her. One has made \$10,272... another is up \$46,002.

[Click here to get her latest pick.](#)

Recent Articles

[This Hot International Market is Trouncing Ours and Paying Double-Digit Yields](#)

By Andy Obermueller
April 15, 2009

This international market has seen a +24% gain this year. But gains are only the beginning of what this country has to offer.

For starters, we found a company that about to become a market leader -- in a recession -- resistant business -- paying a yield of 20.3%.

[Read On...](#)

[The Rarest Security on Earth Carries An Average 17.2% Dividend Yield](#)

By Carla Pasternak
April 8, 2009

Are you looking for a

But just as the flu isn't isolated to Mexico, neither were the losers. All travel and tourist-related companies had a tough time. Houston-based Continental Airlines (NYSE: CAL) lost -16.4%. And on average, casino companies posted double-digit losses for the day.

The Short-Term Winners

Currently there is no vaccine for swine flu, but antiviral medications have proven to be effective treatments. Predictably, the makers of the antiviral medications used to treat swine flu were up; Roche Holding AG produces TAMIFLU while GlaxoSmithKline (NYSE: GSK) manufactures Relenza. Even the shares of Gilead Sciences (Nasdaq: GILD), which gets a percentage of Roche's Tamiflu sales were up.

Quidel (Nasdaq: QDEL) is one of the companies that manufactures diagnostic kits for swine flu. The company's stock exploded on Monday. And tiny Alpha Pro Tech (AMEX: APT), with a market cap of just \$41m, saw its share price climb +31.6% on Monday. The company makes disposable protective apparel and infection control products.

One interesting beneficiary was Netflix (Nasdaq: NFLX). Speculating that people would rather stay at home to watch a movie, rather than risk mingling in public theaters, NFLX stock was up +8.5% on the day.

Thinking Longer-Term

As much as it is on our minds today, this tragic swine flu outbreak will eventually be contained. Our collective hope is for that to happen as quickly as possible and with minimal loss of life. When it's run its course, the vast majority of us will put it behind us. Sales of medications will drop off. Diagnostic kits will sit on the shelves. And the temporary boost to most companies will be over.

But for some companies, this outbreak will have consequential benefits to their long-term growth; companies that produce vaccines.

As governments around the world now scramble to ensure there are adequate supplies of antiviral medications, each and every one of them is wishing they had a vaccine to better protect their populations instead. And they will -- and probably in the very near future.

On Monday, I thought about one company in particular. It already makes regular flu vaccines and is poised to turn around a swine flu vaccine. I thought of the company because I had recently read a profile about it in StreetAuthority newsletter, [High-Yield International](#) -- just weeks before the outbreak.

This company was *High-Yield International's* April "High-Yield Security of the Month." It's a company with a solid track record and an equally solid dividend yield of 5.8%. It also has consistently grown its dividend over the last five years -- [by +157%](#).



-- Amy Calistri
Investment Strategist
Global Dividend Opportunities
GlobalDividends.com
839-K Quince Orchard Blvd.
Gaithersburg, MD 20878-1614

P.S. It's hard to beat the market once the headlines break. The short-term winners and losers move within minutes. But fewer people think long-term. And even fewer have the advantage of top quality research like readers get from

way to grow \$10,000 into \$35,598? How about the opportunity to turn \$25,000 into \$88,994? You can do it with a rare security that blends stocks and bonds. Only eight of them exist. Carla Pasternak, editor of *High-Yield Investing*, explains what these securities are and how they work. The only question is: Why aren't they juicing the returns in your portfolio?

[Read On.](#)

We're Finding Stocks Paying \$26,500 a Year in Dividends

Now is a great time to invest. Every dollar we're investing is giving us two, three, four even five times as much income as it did just a year ago -- it's as if a giant "multiply your money" certificate has dropped into our laps.

[Click here to learn more.](#)

Reader Favorites

[Escape the U.S. Financial Turmoil](#)

By Andy Obermueller

[How to Add a Margin of Safety to Your Stock Portfolio in a Tumultuous Market](#)

By Andy Obermueller

Special Offers

[The Next Way the Government Will Make Investors Rich](#)

The *StreetAuthority Investor Update* is a free weekly newsletter designed to help you track down the market's most profitable stocks,

High-Yield International. If you'd like to learn more about this publication, [please visit this link](#).

P.S.S. -- Don't miss a single issue! Add our address, Research@GlobalDividend.com, to your Address Book or Safe List. For instructions, [go here](#).

funds, and ETFs. Sign up today and you'll also receive a free in-depth research report -- *The Next Way the Government Will Make Investors Rich.*

[Home](#) | [Issue Archives](#) | [About Us](#) | [Meet the Staff](#) | [Subscribe](#)
[Premium Content](#) | [Research Reports](#) | [Media Coverage](#) | [Testimonials](#)

We sincerely hope that you benefit from your subscription to this newsletter, and we're willing to do whatever it takes to keep you as a satisfied customer. However, if at any time you wish to discontinue your complimentary subscription, you can do so by simply [visiting this link](#) and confirming your request, or by calling (301) 216-2005.

Please note that StreetAuthority, LLC is not a registered investment firm or broker/dealer. Readers are advised that the material contained herein should be used solely for informational purposes. StreetAuthority does not purport to tell or suggest which investment securities members or readers should buy or sell for themselves. Site users should always conduct their own research and due diligence and obtain professional advice before making any investment decision. StreetAuthority will not be liable for any loss or damage caused by a reader's reliance on information obtained in this newsletter or on our web site. Our readers are solely responsible for their own investment decisions.

The information contained herein does not constitute a representation by the publisher or a solicitation for the purchase or sale of securities. Our opinions and analyses are based on sources believed to be reliable and are written in good faith, but no representation or warranty, expressed or implied, is made as to their accuracy or completeness. All information contained in this report should be independently verified with the companies mentioned. The editor and publisher are not responsible for errors or omissions. StreetAuthority receives no compensation of any kind from any companies that may be mentioned in our newsletters or on our web site. Any opinions expressed are subject to change without notice. Owners, employees and writers may hold positions in the securities discussed in this report or on our web site.

(C) Copyright 2001-2010. StreetAuthority LLC All Rights Reserved.
Unauthorized Reproduction or Distribution is Strictly Prohibited.